...dang!...try saying that three times in a row real fast!...HAW!...anyway, I see the frequency of this disease is about ONE in a MILLION!...whooeeeee!...that makes the total number of patients in the US around -- what -- 200 , give or take..
...200????...ain't it going be kinda hard to make any money off a drug for just 200 people?...well, what's a few shareholder bucks when you're trying to do domething noble -- right?...
...and RTRX thinks this RE-024 has potential because of this:
"Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatment of the ultra-orphan disease Pantothenate Kinase-Associated Neurodegeneration (PKAN).....Tests were conducted on mice that were administered a PANK inhibitor to induce a PKAN-like phenotype....The interim results of this two-week study assessed the effect of RE-024 in mice...(37/40) of the mice..."
...now, let me get this straight -- RTRX is planning on spending who knows how many millions of shareholder equity on an "ultra-orphan" disease based on a TWO WEEK study of FORTY MICE that were INDUCED to have a "PKAN-like" phenotype -- in other words, they didn't even have the mutation in the PANK2 gene?...is that about it?...hold on a second: